MDXXF Stock Chart & Stats
$0.11
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$0.06 - $0.15
Previous CloseN/A
VolumeN/A
Average Volume (3M)17.70K
Market Cap
$10.78M
Enterprise Value$15.68M
Total Cash (Recent Filing)$564.71K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Jul 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding108,887,215
10 Day Avg. Volume7,350
30 Day Avg. Volume17,697
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue17.62
Enterprise Value/Gross Profit-29.94
Enterprise Value/Ebitda-10.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized GMP Supplier ModelPharmAla’s focus on GMP-grade MDMA for regulated clinical and research customers is a durable niche business model. High regulatory and quality barriers limit competition, creating a specialized supplier role that can capture recurring institutional demand as clinical trials and regulated use expand over time.
Debt-free Balance SheetZero financial leverage materially reduces solvency and interest burden risk, providing strategic flexibility to fund regulatory work or capacity build without immediate debt pressures. This preserves optionality for equity financing or partnerships during multi-year drug development cycles.
Top-line Growth TrendRevenue growth indicates expanding commercial traction with research and clinical customers. Sustained top-line expansion, if maintained, supports scaling fixed-cost absorption, improves negotiating leverage with suppliers, and underpins longer-term path to profitability as the regulated MDMA market matures.
Bears Say
Negative Unit EconomicsNegative gross profit signals the company is losing money on core product deliveries, implying current pricing or cost structure is unsustainable. Without durable margin improvement—via pricing, mix, or cost reduction—unit losses will erode capital and make scale unprofitable even with revenue growth.
Persistent Cash BurnContinued negative operating and free cash flows mean the business depends on external funding for operations and growth. This raises dilution risk, constrains ability to invest in manufacturing scale or compliance, and can limit resilience to regulatory or market setbacks over the next several quarters.
Lack Of Secured Long-term Commercial ContractsAbsence of documented long-term partnerships or recurring revenue sources creates revenue unpredictability during commercialization. For a regulated, development-dependent product category, lacking contracted demand increases execution risk and weakens the revenue runway needed to justify sustained investment.
PharmAla Biotech Holdings, Inc. News
MDXXF FAQ
What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?
PharmAla Biotech Holdings, Inc. lowest stock price was $0.06 and its highest was $0.15 in the past 12 months.
What is PharmAla Biotech Holdings, Inc.’s market cap?
PharmAla Biotech Holdings, Inc.’s market cap is $10.78M.
When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?
PharmAla Biotech Holdings, Inc.’s upcoming earnings report date is Jul 24, 2026 which is in 9 days.
How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?
PharmAla Biotech Holdings, Inc. released its earnings results on Apr 21, 2026. The company reported -$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is PharmAla Biotech Holdings, Inc. overvalued?
According to Wall Street analysts PharmAla Biotech Holdings, Inc.’s price is currently Undervalued.
Does PharmAla Biotech Holdings, Inc. pay dividends?
PharmAla Biotech Holdings, Inc. does not currently pay dividends.
What is PharmAla Biotech Holdings, Inc.’s EPS estimate?
PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmAla Biotech Holdings, Inc. have?
PharmAla Biotech Holdings, Inc. has 108,887,215 shares outstanding.
What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?
PharmAla Biotech Holdings, Inc. reported an EPS of -$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.5%.
Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?
Currently, no hedge funds are holding shares in MDXXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmAla Biotech Holdings, Inc.
Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. The company's offerings further extend to various MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB) and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), in addition to prepared formulations of these MDXX substances. The enterprise maintains its primary corporate offices in Vancouver, Canada.
Ownership Overview
Options Prices
Currently, No data available
---